Business Monitor International


Kenya Pharmaceuticals & Healthcare Report

Published 15 August 2014

  • 111 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Kenya Pharmaceuticals & Healthcare Report

BMI View:   The rising non-communicable disease burden will boost demand for prescription medicines to treat chronic diseases in Kenya. However, we believe drugmakers cannot employ their developed state business models to market medicines in a country that has traditionally focussed on the treatment of infectious diseases such as malaria, tuberculosis and HIV. Besides challenges related to diagnosis, care and treatment, there is a lack of understanding and knowledge about diseases such as diabetes and cancer among healthcare professionals and the general population, and a perception that these diseases are not as critical as other s affecting the country. Furthermore, limited government contribution to healthcare and low affordability levels create the need to establish structured channels through which companies can boost the use of their products - particularly as in an emerging market like Kenya, the demand for medicines is not equal to the uptake of medicines.

Headline Expenditure Projections

  • Pharmaceuticals: KES55.29bn (USD642mn) in 2013 to KES63.77bn (USD725mn) in 2014; 15.3% growth in local currency terms and 12.9% in US dollar terms.

  • Healthcare: KES184.28bn (USD2.14bn) in 2013 to KES207.59bn (USD2.36bn) in 2014; 12.6% growth in local currency terms and 10.2% in US dollar terms.

Risk/Reward Index

In BMI's Q115 Pharmaceutical and Healthcare Risk/Reward Index  (RRIs), Kenya is 18th in the Middle East and Africa (MEA) region. A large counterfeit drug industry, poor healthcare funding, corruption, regulatory deficiencies and a number of other issues will conspire to keep Kenya in a low position in the MEA matrix. Nevertheless, in comparison with many other African markets, most of which are not surveyed by BMI, Kenya offers greater commercial promise and a more stable overall business environment.

Key Trends And Developments

In October 2014, the Kenyan Ministry of Health stated that it would press for information on the ongoing international...

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Business Environment
12
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Kenya 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Kenya 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Kenya 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Kenya 2010-2018)
19
Prescription Drug Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Kenya 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Kenya 2010-2018)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Kenya 2010-2018)
24
Kenya
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Kenya 2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Kenya 2012-2018)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Kenya 2012-2018)
28
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
34
Table: Kenya - GDP By Expenditure
41
Industry Risk Reward Ratings
42
Middle East & Africa Risk/Reward Ratings
42
Kenya Risk/Reward Ratings
49
Rewards
49
Risks
49
Market Overview
51
Industry Trends And Developments
53
Epidemiology
53
Healthcare Provision
56
Healthcare Sector Financing
56
Health Insurance
57
Private Healthcare
60
Supply Chain
62
Research & Development
63
Clinical Trials
66
Regulatory Development
68
Regulatory Regime
68
Intellectual Property
69
Pricing & Reimbursement Regime
69
Competitive Landscape
71
Pharmaceutical Industry Activity
73
Company Profile
75
Dawa Limited
75
Universal Corporation Limited
77
Shelys Pharmaceuticals
79
Regal Pharmaceuticals
81
High Chem East Africa
82
GlaxoSmithKline
83
Pfizer
86
Novartis
89
Sanofi
92
Merck & Co
94
Demographic Forecast
96
Table: Kenya's Population By Age Group, 1990-2020 ('000)
97
Table: Kenya's Population By Age Group, 1990-2020 (% of total)
98
Table: Kenya's Key Population Ratios, 1990-2020
99
Table: Kenya's Rural And Urban Population, 1990-2020
99
Glossary
100
Methodology
102
Pharmaceutical Expenditure Forecast Model
102
Healthcare Expenditure Forecast Model
102
Notes On Methodology
103
Risk/Reward Ratings Methodology
104
Ratings Overview
105
Table: Pharmaceutical Risk/Reward Ratings Indicators
105
Indicator Weightings
106

The Kenya Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kenya Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kenyan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kenya to test other views - a key input for successful budgeting and strategic business planning in the Kenyan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Kenyan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kenya.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc